Mimesis Law
3 June 2020


  • Biogen Slips Out of Bass’ Grasp In IPR Play

    by - Sep 4, 2015
    (Comments: 2)
    Sept 4, 2015 (Mimesis Law) — The third time was not a charm for Kyle Bass’ IPR efforts as the PTAB rejected his attack on a key Biogen patent – the ‘514 Patent which protects over a...
  • Markman Minute: Unpacking Forward Pharma

    by - May 26, 2015
    (Comments: 0)
    May 26, 2015 (Mimesis Law) — Gaston tackles the complicated situation situation surrounding the intellectual property for Forward Pharma’s multiple sclerosis treatments. Is FWP a buy or are investors in the company building a “house on...
  • Markman Note: Is Bass Going To Eat FWP’s Lunch?

    by - May 19, 2015
    (Comments: 1)
    May 17 , 2015 (Mimesis Law) — Forward Pharma’s (FWP) story is an interesting one. A recent IPO, Forward’s main assets are intellectual property and development prospects surrounding treatments for multiple sclerosis. In fact, one of the...

Cy-Pher Mailing List

Subscribe to our mailing list

* indicates required